Clinical Trial Update: Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke [Phase 1]

View source ↗

Summary

This update covers a Phase 1 safety study of carbamylated erythropoietin (CEPO) for acute ischemic stroke, sponsored by H. Lundbeck A/S. The trial status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Carbamylated Erythropoietin (carbamylated erythropoietin)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Acute Ischemic Stroke | Phase 1 | Status: COMPLETED